These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 19698378)

  • 1. Genotypes of cytochrome P450 and clinical response to clomipramine in patients with major depression.
    Bouchez J; Dumur V; Lhermitte M; Goudemand M
    Eur Psychiatry; 1995; 10(8):410-2. PubMed ID: 19698378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Danish University Antidepressant Group.
    Nielsen KK; Brøsen K; Gram LF
    Eur J Clin Pharmacol; 1992; 43(4):405-11. PubMed ID: 1451721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism.
    Ebner T; Eichelbaum M
    Br J Clin Pharmacol; 1993 Apr; 35(4):426-30. PubMed ID: 8485023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytochrome P450: genetic polymorphism and drug interactions.
    Belpaire FM; Bogaert MG
    Acta Clin Belg; 1996; 51(4):254-60. PubMed ID: 8858891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of the sparteine/debrisoquine oxidation polymorphism.
    Brøsen K; Gram LF
    Eur J Clin Pharmacol; 1989; 36(6):537-47. PubMed ID: 2570698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics of antidepressants: clinical aspects.
    Bertilsson L; Dahl ML; Tybring G
    Acta Psychiatr Scand Suppl; 1997; 391():14-21. PubMed ID: 9265947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of cytochrome P450 isoform activities in the female dark agouti (DA) rat: relevance to its use as a model of the CYP2D6 poor metaboliser phenotype.
    Barham HM; Lennard MS; Tucker GT
    Biochem Pharmacol; 1994 Apr; 47(8):1295-307. PubMed ID: 8185638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics of clomipramine.
    Balant-Gorgia AE; Gex-Fabry M; Balant LP
    Clin Pharmacokinet; 1991 Jun; 20(6):447-62. PubMed ID: 2044329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Role of pharmacogenetics in psychopharmacotherapy].
    Gram LF
    Encephale; 1991; 17 Spec No 1():123-5. PubMed ID: 1864259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The significance of cytochrome P450 gene superfamily for the clinical pharmacokinetics of drugs].
    Brøsen K
    Ugeskr Laeger; 1991 Feb; 153(6):417-22. PubMed ID: 2000644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms.
    Nielsen KK; Brøsen K; Hansen MG; Gram LF
    Clin Pharmacol Ther; 1994 May; 55(5):518-27. PubMed ID: 8181196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cytochrome p450 IID6, its role in psychopharmacology].
    Lamard L; Pérault MC; Bouquet S; Guibert S
    Ann Med Psychol (Paris); 1995 Feb; 153(2):140-3. PubMed ID: 7741408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity.
    Neafsey P; Ginsberg G; Hattis D; Sonawane B
    J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):334-61. PubMed ID: 20183526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacogenetics of antidepressant metabolism. Value of the debrisoquin test].
    Baumann P
    Encephale; 1986; 12(4):143-8. PubMed ID: 3792273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The influence of clomipramine on CYP2D6 activity].
    Szewczuk-Bogusławska M; Kiejna A; Grzesiak M; Beszłej JA; Chlebowska I; Orzechowska-Juzwenko K; Milejski P
    Psychiatr Pol; 2007; 41(2):243-9. PubMed ID: 17598433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2D6 phenotypes among Malays in Malaysia.
    Ismail R; Hussein A; Teh LK; Nizam Isa M
    J Clin Pharm Ther; 2000 Oct; 25(5):379-83. PubMed ID: 11123490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular genetic analysis of the cytochrome P450-debrisoquine hydroxylase locus and association with cancer susceptibility.
    Smith CA; Moss JE; Gough AC; Spurr NK; Wolf CR
    Environ Health Perspect; 1992 Nov; 98():107-12. PubMed ID: 1486838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.
    Llerena A; Dorado P; Peñas-Lledó EM
    Pharmacogenomics; 2009 Jan; 10(1):17-28. PubMed ID: 19102711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline.
    Roberts RL; Mulder RT; Joyce PR; Luty SE; Kennedy MA
    Hum Psychopharmacol; 2004 Jan; 19(1):17-23. PubMed ID: 14716707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.
    Zanger UM; Raimundo S; Eichelbaum M
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Jan; 369(1):23-37. PubMed ID: 14618296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.